Visitors   Views   Downloads

Bridging the TB data gap: in silico extraction of rifampicin-resistant tuberculosis diagnostic test results from whole genome sequence data

View article
RT @con_meehan: We (well mostly @kamela_ng) wrote a little tool to convert #WGS results into Xpert probe information, to allow for cross-pl…
RT @con_meehan: We (well mostly @kamela_ng) wrote a little tool to convert #WGS results into Xpert probe information, to allow for cross-pl…
RT @buttonricarte: Congratulations to my favorite scientist '@kamela_ng for another publication!
Congratulations to my favorite scientist '@kamela_ng for another publication!
RT @con_meehan: We (well mostly @kamela_ng) wrote a little tool to convert #WGS results into Xpert probe information, to allow for cross-pl…
RT @con_meehan: We (well mostly @kamela_ng) wrote a little tool to convert #WGS results into Xpert probe information, to allow for cross-pl…
49 days ago
RT @con_meehan: We (well mostly @kamela_ng) wrote a little tool to convert #WGS results into Xpert probe information, to allow for cross-pl…
49 days ago
RT @con_meehan: We (well mostly @kamela_ng) wrote a little tool to convert #WGS results into Xpert probe information, to allow for cross-pl…
We (well mostly @kamela_ng) wrote a little tool to convert #WGS results into Xpert probe information, to allow for cross-platform comparisons of #TB diagnostics results.
  1. October 3, 2019: Minor Correction The Figure 3C legend is incomplete and should read: "Distribution of RR-TB cases and Xpert Classic probe reactions predicted in silico from whole genomes collected in 2005 to 2010 in Rwanda and actual Xpert Classic results gathered in 2012 to 2017. The distribution of Xpert Classic absent probe E was overlaid on the documented RR-TB case counts and plotted against the notified RR-TB case counts from surveillance programs and national surveys in Rwanda."


Resistance to rifampicin (RIF), the most potent anti-tuberculosis (TB) drug, hampers TB control. RIF-resistant (RR)-TB persists as an urgent public health crisis as only 29% of estimated RR-TB patients worldwide were detected and notified in 2017. Further, 18% of previously treated TB patients were found to have RR-TB (WHO, 2018). The WHO endorsed the following rapid molecular RR-TB diagnostic test (RDTs) to address this concern: Xpert MTB/RIF (Xpert Classic) and the new version Xpert MTB/RIF Ultra (Ultra) (Cepheid, Sunnyvale, CA, USA) which employ heminested real-time polymerase chain reaction and molecular beacon technology (Blakemore et al., 2010); and the line probe assays—GenoType MDRTBplus v2.0 (hereinafter called LPA-Hain) (Hain Lifescience GmbH, Nehren, Germany); and GenoscholarNTM+MDRTB II (hereinafter called LPA-Nipro) (NIPRO Corporation, Osaka, Japan) which rely on multiplex amplification and reverse hybridization of target to both wild-type and mutant probes on a membrane strip (Dheda et al., 2017). These tests were designed to detect RR-conferring mutations within the RIF resistance determining region (RRDR) or hotspot of the rpoB gene (Andre et al., 2017; Blakemore et al., 2010; Ng et al., 2018a, 2018c).

The Xpert assay involves binding of five short overlapping fluorescent probes to wild-type regions of the RRDR. Each of the five probes corresponds to several mutations which inhibit probe binding, thereby disrupting the signal from the respective probe. Thus, when a mutation is detected by Xpert, at least one probe does not bind. Certain mutations which completely interfere with probe binding result in “drop-out” or absent probe, whereas mutations that allow limited probe hybridization are represented by “delayed” probes (Blakemore et al., 2010). Xpert probes are therefore often considered as a proxy for circulating RIF resistance-conferring mutations which may be common or infrequent in a particular country. Understanding their frequency can be crucial for RIF resistance surveillance. For example, mutation Ser450Leu repeatedly detected globally (Coll et al., 2018; Walker et al., 2015) is captured by “absent” Xpert probe E (Ng et al., 2018a).

The implementation of Xpert was a breakthrough in TB diagnosis as it revolutionized the detection of RR-TB worldwide, allowing for prompt identification of patients who need to undergo adapted treatment. Xpert Classic is the most widely deployed RDT globally, implemented as the initial diagnostic tool for all presumptive pulmonary TB patients by 32 out of 48 high TB-burden countries (WHO, 2018). The wide utilization of the tests in both low and high burden TB countries resulted in the production of large volumes of RDT data, although comparisons within and between countries can be difficult due to use of differing technologies.

The utility of next-generation sequencing technologies has been widely studied for improved detection of drug-resistant TB in diverse laboratory settings worldwide (Gardy & Loman, 2018). Next-generation sequencing-based whole genome sequencing (WGS) of Mycobacterium tuberculosis (Mtb) has been shown to accurately detect RR-TB by calling relevant single nucleotide polymorphisms (SNPs) in the rpoB gene (Coll et al., 2018; Miotto et al., 2017). Whole genome sequencing is already being widely implemented in the United Kingdom, the Netherlands, and New York, aimed towards completely replacing phenotypic drug susceptibility testing in the clinic (CRyPTIC Consortium and the 100,000 Genomes Project et al., 2018; de Viedma, 2019). Whole genome sequencing implemented in high burden TB countries was shown to accurately estimate the prevalence of DR-TB (Zignol et al., 2018). The conventional periodic TB drug resistance surveys have been gathering data representative of the Mtb population in poor resource settings, while high-income countries typically apply continuous surveillance (WHO, 2018; Zignol et al., 2018), to help improve the choice of standard TB treatment before full drug sensitivity profile is known (WHO, 2018).

The increasing use of WGS in research and public health initiatives can lead to a disconnect from the RDT-based data being generated routinely in the clinic, and the majority of surveys, widening the Mtb data gap. We aim to bridge this Mtb data gap by transforming WGS data into each of the related RDT data outputs, to facilitate analysis of RR-TB prevalence and underlying mutations regardless of the switch between data generation technologies. This will allow end-users to compare “apples with apples,” and analyze previous historical strains with current isolates representative of the entire TB patient population in the country.

We present the MycTB Genome to Test (MTBGT) tool, a Python 3-based set of scripts that rapidly transform WGS data type into RDT and mutation reports. The modules automatically generate frequencies of RIF-susceptible (RS) and RR-TB samples detected and supplement the RDT probes output with the detected RR-conferring mutation in the format of “wild-type amino acid-codon number-mutant amino acid.”

Materials and Methods

We developed the MTBGT tool, a Python 3-executable that converts Mtb WGS data in the form of variant call format (VCF) or MTBseq (Kohl et al., 2018) tab files into the most likely output that would be observed from Xpert Classic, Xpert Ultra, LPA-Hain, and LPA-Nipro based on previously validated work (Ng et al., 2018a, 2018c). The MTBGT tool can be accessed at

The MTBGT tool

The MTBGT tool can be run on any python 3-enabled operating system with no additional prerequisites. The MTBGT workflow is shown in Fig. 1. The input is a folder of files derived from an SNP calling pipeline, either in standard raw VCF format or tab format as output from MTBseq. The MTBGT tool assumes the standard H37Rv NC000962.3 genome was used for calling these SNPs. If not, the user may remap the genome positions to the specific RR-TB-related codons using a tab-delimited mapping file. An example of this tab-separated file is bundled with the tool. By default, the module will run all the RDTs on the input files.

The MTBGT tool workflow.

Figure 1: The MTBGT tool workflow.

The generated tab-delimited output file includes the Sample name, RIF resistance or susceptibility, the associated mutant codon position and mutation pattern, and a series of 0’s or 1’s indicating absence or presence of the capturing probe for the RDTs, and the RR-conferring mutation (an example output is given in Table 2). A summary table with counts and proportions of detected RS-TB cases, RDT probes, and RR-conferring mutations is also generated (Table S1). These tab-separated output files can be easily imported into Excel as outlined in the associated manual.

Table 1:
Rifampicin resistance (RR)-conferring mutations and associated rapid diagnostic test (RDT) results, previously tested and validated*, and used as basis for developing the MTBGT tool.
RR-TB RDT RR mutation
Xpert Classic Xpert Ultra LPA-Hain LPA-Nipro
Capturing probe Capturing probe Melting temperature shift Absent (WT) probe Developing (MUT) probe Absent (WT) probe Developing (MUT) probe
Probe A rpoB1 3.5 WT1 S1 Ser428Arg
Probe A rpoB1 5.9–6.3 WT2 S1 Leu430Pro
Probe A, Probe B rpoB1 2.9 WT2 S1 Ser431Gly
Probe B rpoB1 3.4 WT2, WT3 S1 Gln432Glu
Probe B rpoB2 3.2 WT3 S2 Met434Ile
Probe B rpoB2 3.3 WT3 S2 Met434Thr
Probe B rpoB1 6.3 WT3 S2 Met434Val
Probe B rpoB2 2.8 WT3, WT4 S2 Asp435Glu
Probe B delayed rpoB2 5.3 WT3, WT4 S2 Asp435Phe
Probe B rpoB2 3.3 WT3, WT4 S2 Asp435Gly
Probe B rpoB2 3.5–3.7 WT3, WT4 MUT1 S2 R2 Asp435Val
Probe B delayed rpoB2 4.0–4.4 WT3, WT4 S2 Asp435Tyr
Probe C rpoB2 6.4 WT4 S2 Asn437Asp
Probe C rpoB2; rpoB3 3.0; 2.3 WT5, WT6 S3 Ser441Leu
Probe C rpoB2; rpoB3 4.7; 2.3 WT5, WT6 S3 Ser441Gln
Probe D rpoB3 3.7–3.9 WT7 MUT2B S4 R4b His445Asp
Probe D rpoB3 4.9 WT7 S4 His445Gly
Probe D rpoB3 3.5–3.6 WT7 S4 His445Leu
Probe D rpoB3 3.4–3.5 WT7 S4 His445Asn
Probe D rpoB3 3.6 WT7 S4 His445Gln (CAG)
Probe D rpoB3 4.1 WT7 S4 His445Gln (CAA)
Probe D delayed rpoB3 1.9 WT7 S4 His445Arg
Probe D rpoB3 4.7 WT7 S4 His445Ser
Probe D rpoB3 4.9 WT7 S4 His445Thr
Probe D rpoB3 3.2–3.3 WT7 MUT2A S4 R4a His445Tyr
Probe D rpoB4B 5.0 WT7 S4 Lys446Gln
Probe E rpoB3 4.0 WT8 S5 Ser450Phe
Probe E rpoB3; rpoB4A 2.5–2.9; 6.0–6.5 WT8 MUT3 S5 R5 Ser450Leu
Probe E rpoB3; rpoB4A 2.3–2.7; 3.3–3.7 WT8 S5 Ser450Trp
Probe E delayed rpoB4B 5.7–6.1 WT8 S5 Leu452Pro
DOI: 10.7717/peerj.7564/table-1


(Ng et al., 2018a, 2018b); Capturing probe, RDT probe associated with the RR-conferring mutation; Melting temperature shift, difference between mutant (MUT) and wild-type (WT) melting temperatures; ND, ‘not detected’, refers to mutations outside the RR determining region, not detected by the RR-TB RDTs.

Validation and sample application of the MTBGT modules

We simulated VCF files for internal validation of the MTBGT modules. We then randomly chose a VCF file and edited it in Notepad++ 7.6.3 ( to contain all previously tested and validated RR-conferring mutations (Andre et al., 2017; Miotto et al., 2017) which were mapped to known RDT results (Ng et al., 2018a, 2018c) (Table 1). We generated files with single and multiple RR mutations to ensure the tool is robust for all scenarios. These simulated VCFs are provided with the tool.

Table 2:
Example of combined results from the MTBGT tool rapid diagnostic test (RDT) modules supplemented by the rifampicin resistance (RR)-conferring mutations detected.
Filename RIF resistance Codon number Codon Xpert Classic Xpert Ultra LPA-Hain LPA-Nipro RR mutation
Capturing probe Probe pattern Capturing probe, melting temperature shift Probe pattern Capturing probe Probe pattern Capturing probe Probe pattern
DRC-052577 Detected 450 TTG Probe E 1 1 1 1 0 1 rpoB3,rpoB4A; 2.5–2.9, 6.0–6.5 1 1 0 0 1 WT8, MUT3 1 1 1 1 1 1 1 0 0 0 0 1 S5, R5 1 1 1 1 0 0 0 0 1 Ser450Leu
DRC-091003 Detected 452 CCG Probe E delayed 1 1 1 1 1 0 rpoB4B; 5.7–6.1 1 1 1 1 0 WT8 1 1 1 1 1 1 1 0 0 0 0 0 S5 1 1 1 1 0 0 0 0 0 Leu452Pro
1993-09004 Detected (only by rpoB Sanger sequencing module) 170 TTC Not detected Not detected Not detected Not detected Val170Phe
DRC-101308 Detected (only by rpoB Sanger sequencing module) 491 TTC Not detected Not detected Not detected Not detected Ile491Phe
DOI: 10.7717/peerj.7564/table-2

To show real-world applicability, the MTBGT tool was run on WGS of RS and RR-TB WHO Tropical Disease Research (TDR) strains with diverse resistance patterns and geographic origins stored in the Belgian Coordinated Collections of Microorganisms in the Institute of Tropical Medicine including the 47 TDR-TB strains tested in the previous validation of the RDTs against the available rpoB Sanger sequences of the strains (Ng et al., 2018a, 2018c; Vincent et al., 2012). The fastQ files (ENA accession PRJEB31023) for these samples were run through the MTBseq pipeline with default settings (Kohl et al., 2018) to generate the tab files for input to MTBGT. Additionally, WGS from 324 phenotypically RR-TB isolates of retreatment TB patients in Kinshasa, the Democratic Republic of Congo (DRC) collected in 2005–2010 (Meehan et al., 2018), and 233 WGS isolated 1991–2010 from Rwanda were subjected to the MTBseq pipeline and run through the MTBGT tool.

We were then able to extract the associated Xpert results from the 1991 to 2010 Rwandan dataset and compare it with actual Xpert results from 2012 to 2017 (Ng et al., 2018b).


We tested the MTBGT tool on a 64-bit Windows 10 Enterprise computer with a 2.50 GHz processor and a 8.00 GB of RAM. The running time was 39 milliseconds for one MTBseq tab file and 530 milliseconds for a VCF file.

The MTBGT tool correctly transformed the WGS-derived SNPs in the VCF and MTBseq tab files into the laboratory-validated RDT probe reactions (Table 2), and accurately detected all previously validated RR-conferring mutations in the simulated VCF and MTBseq clinical WGS data from the TDR, DRC (Figs. 2A and 2B), and Rwanda (Figs. 3A and 3B) strains, including double nucleotide changes—two SNPs covering two loci or genome positions—such as the CAC → AGC and CAC → TCC His445Ser mutations and combinations of any two unlinked mutations. The generated frequency and proportion tables (Table S1) showed the distribution of the RS and RR-TB strains, the RDT probe reactions, and the RR-conferring mutations detected.

Distribution of (A) rifampicin-sensitive samples and Xpert Classic probes, and (B) rifampicin resistance-conferring mutations among rifampicin-resistant tuberculosis isolates in Kinshasa, DRC from 2005 to 2010, detected by the MTBGT tool.

Figure 2: Distribution of (A) rifampicin-sensitive samples and Xpert Classic probes, and (B) rifampicin resistance-conferring mutations among rifampicin-resistant tuberculosis isolates in Kinshasa, DRC from 2005 to 2010, detected by the MTBGT tool.

Distribution of (A) rifampicin-sensitive samples and Xpert Classic probes, and (B) rifampicin resistance-conferring mutations among rifampicin-resistant tuberculosis isolates in Rwanda from 1991 to 2010, determined by the MTBGT tool and (C) distribution of r.

Figure 3: Distribution of (A) rifampicin-sensitive samples and Xpert Classic probes, and (B) rifampicin resistance-conferring mutations among rifampicin-resistant tuberculosis isolates in Rwanda from 1991 to 2010, determined by the MTBGT tool and (C) distribution of r.

The in silico extracted Xpert results from the Rwandan WGS collected in 1991–2010 revealed that the majority of RR-TB cases detected were linked with Xpert Classic probe E (Fig. 3A). This observation was consistent with the actual Xpert results gathered in 2012–2017. Figure 3C shows the distribution of 12 years worth of Xpert results in Rwanda. The MTBGT tool facilitated this continuous analysis of in silico predicted Xpert results from 2005 to 2010 WGS and actual Xpert results in 2012–2017, and allowed us to plot the distribution of absent probe E against the notified RR-TB cases from surveillance programs and national surveys in Rwanda. The low WGS sampling reflected in Fig. 3C is explained by the limited TB cultures kept in the freezer in 2005–2010. Notably, we also observed the divergence of documented probe reactions from the predominant absent probe E in 2013–2017.

Xpert Classic probe E was also predominantly seen in samples from Kinshasa, DRC (Fig. 2A; Table S1). Mutation Ser450Leu, linked with Xpert Classic probe E, was the major RR-conferring mutation observed in both settings (Figs. 2B and 3B).


To make sense of the increasingly produced WGS in light of the existing and readily available routine RDT results, we developed, validated, and applied the MTBGT, a Python-implemented tool that extracts RR-TB RDT results and RR-conferring mutations from WGS-derived SNP data.

If a country performed prior drug resistance surveys with a different diagnostic algorithm, the MTBGT tool allows for comparing data of different formats and sources, facilitating analysis of previous and current RR-TB case counts, probe reactions, and mutations, such as periodic DRS results conducted as cross-sectional surveys, often with different technology from the previous one. Although WGS data give a much higher resolution than the RDTs, low- and middle-income high RR-TB burden countries are not yet capable of implementing routine WGS for all presumptive TB patients due to limitations in funding and logistic challenges (Meehan et al., 2019). However, RDTs are used routinely in such countries, producing a wealth of RR-TB data, whereas WGS is used for regular country-wide drug resistance surveys by the WHO (Zignol et al., 2018), and implemented in low burden high-income countries. But since RDT results cannot be upscaled to WGS results, for comparison of these two data sources, WGS must be downscaled to the RDT results. By downscaling, the MTBGT tool adds to a substantial history of RDT probe data which amplifies surveillance analyses that can inform national TB control programs (NTPs) of low- and middle-income settings. This is similar to how CRISPR-based strain typing of M. tuberculosis (termed spoligotyping) can be predicted from WGS reads through SpoTyping (Xia, Teo & Ong, 2016). Although spoligotyping is known to have a lower resolution than WGS for typing, it is still widely used in many low- and middle-income TB endemic countries due to its low cost (Montoya et al., 2013; Suzana et al., 2017; Tulu & Ameni, 2018). We foresee our tool being used in a similar manner, until WGS capabilities become more commonplace in low- and middle-income high RR-TB burden countries.

We show in Fig. 3C how the MTBGT tool would be beneficial in Rwanda, a low-income country which uses Xpert for routine diagnostics and WGS for WHO-led 5-year drug resistance surveys and selected research projects. Figure 3C reflects continuous distribution of RR-TB cases and Xpert absent probe E in Rwanda for more than a decade. These trends of RR-TB and absent probe E boost surveillance analyses that can inform the Rwandan NTP and support public health efforts for improved RR-TB control. The MTBGT tool allows for such comparisons and continuous distributions to be made, enabling low- and middle-income researchers to utilize all of their data for surveillance of RR-TB. This analysis of Rwandan datasets is a proof-of-concept that the MTBGT tool provides an opportunity to compare and analyze old and new data produced by different technologies bridging the RR-TB data gap. Care must be taken that the comparison is valid given the populations sampled. The predominant Xpert Classic probe E observed in Rwanda is supported by the associated RR mutation Ser450Leu (Tables 1 and 2) being present in the primary circulating multidrug-resistant TB clone in this setting (Ngabonziza et al., 2018), and also most frequently associated with global RR-TB (Cohen et al., 2015; Coll et al., 2018; Georghiou et al., 2016).

Programmatic surveillance is possible with only the RIF susceptibility status of patients’ samples, but at a different level. The RDT probe information which represents the underlying RR-conferring mutation provides an added critical value for epidemiological studies and surveillance (Ng et al., 2018b). This is exemplified by Xpert probe B and probe binding delay in South Africa being associated with false RR-TB results (Berhanu et al., 2019). In this setting, patients who were true RS but diagnosed as RR were treated with less effective and more toxic multidrug-resistant TB drugs relative to the standard TB treatment. Further, non-routine WGS alone may give incorrect distribution of circulating mutations in the setting due to culture and sampling biases, as shown by the limited stored cultures resulting in low WGS sampling in Rwanda in 2005–2010.

Settings which employ different RDTs can refer to Table 1 where they can match laboratory-validated Xpert Classic and Xpert Ultra probe signatures with a specific RR-TB mutation type (Ng et al., 2018a, 2018c). This would be helpful for settings such as South Africa which implements Xpert Classic and concurrently transitions to Xpert Ultra (Berhanu et al., 2018), and many other countries that will shift to Xpert Ultra in the near future, such as Rwanda by 2020.

The genome-based approach of the MTBGT tool also allows for reporting of disputed mutations that confer occult RR and are frequently missed by the Mycobacterium Growth Indicator Tube phenotypic DST (Ng et al., 2018a; Van Deun et al., 2015). For instance, disputed mutation Leu452Pro, epidemiologically linked with an extensively drug-resistant TB outbreak in KwaZulu-Natal, South Africa in 2005 (Cohen et al., 2015; Ioerger et al., 2009), was detected in some strains from Kinshasa, DRC, and Rwanda (Figs. 2B and 3B; Supplemental File). Mutation Leu452Pro is captured by delayed Xpert Classic probe E, denoting partially inhibited probe E fluorescence (Lawn & Nicol, 2011; Ng et al., 2018a), and specifically identified by the unique combination of Xpert Ultra probe rpoB4B and corresponding melting temperature shift (Table 1), provided sufficient Mtb DNA is detected. Further, mutation Leu452Pro was reported to be missed in clinical samples by LPA-Hain due to its end-probe location (Al-Mutairi, Ahmad & Mokaddas, 2011; Rigouts et al., 2013), thus contributing to the RR-TB detection gap. The ability of the MTBGT tool to rapidly and accurately detect disputed mutations is therefore important.

As a supplementary feature, the MTBGT tool picks up any RR-conferring mutation present in the VCF or MTBseq tab file, and may help assess whether RDTs sufficiently detect RR-TB cases in specific settings.

Looking into the future when WGS will be implemented as the primary diagnostic tool for all presumptive TB patients to confirm TB and/or RR-TB, the MTBGT tool will bridge the TB data gap by allowing comparison of past Xpert and LPA results with current in silico predicted results from routine whole genome sequences. These data would be comparable based on a common statistical parameter and representative of the presumptive TB population in the setting. With more whole genomes of M. tuberculosis sequenced, the in silico predicted probe distribution will more accurately capture the circulation of RR-TB mutations in the setting. The tool can do so by precisely revealing the divergence of current probes from a previously documented predominant probe over time, implicative of other circulating mutations such as that shown by actual Xpert results in 2013–2017 (Fig. 3C).

The MTBGT tool was developed to aid surveillance efforts of low- and middle-income high RR-TB burden countries with likely fragmented data collection systems (Mazumdar, Satyanarayana & Pai, 2019). Through facilitated continuous analysis of previous historical and current RR-TB data, as well as clinical data from large aggregated files and routine laboratory and periodic survey RDT results combined with WGS-derived data from national surveillance programs and public data repositories, the MTBGT tool may create a larger picture of the RS-TB and RR-TB burden in a country. The RS and RR-TB counts and proportions and RDT probe reactions generated by the MTBGT tool may contribute to an extensive database with years’ worth of data for continuous statistical modeling analyses and surveillance investigations.

Potentially, the MTBGT tool may be integrated in the national TB diagnostic algorithm through the existing information system and connectivity platform or the newly implemented WHO cloud-based software (Dean, 2019). The prospective application of the MTBGT tool may bridge and transform the Mtb data gap into action points for RR-TB clinicians to provide appropriate care for the individual TB/RR-TB patient, and the NTP, public health officials, and policy makers to intervene at the population-level for improved and sustained RR-TB control (Gardy & Loman, 2018). The MTBGT modules could also be expanded to report non-RRDR RR-conferring mutations and include other TB drugs—e.g. isoniazid, pyrazinamide, and fluoroquinolones.


The MTBGT tool leverages improved access to next-generation sequencing technologies in this genomic epidemiology era of TB, and complements Mtb WGS by rapidly transforming WGS files that store genomic sequence variations to validated outputs of the RR-TB RDTs. The prospective application of the MTBGT tool within a nationwide genomic epidemiology program will bridge the Mtb data gap among routine RDT data, research setting WGS, and periodic survey and continuous surveillance rpoB sequencing and WGS data. This may result in facilitated continuous analysis of the circulating RDT probes and underlying distribution of RR-conferring mutations in the setting, and may help assess whether currently implemented RDT(s) serve the detection of RR-TB cases in the country.

Supplemental Information

Summary tables of counts and proportions of rifampicin-susceptible TB samples, rapid diagnostic test probes, and rifampicin-resistant TB mutations detected by the TBGT tool from the 2005 to 2010 isolates in Kinshasa, DRC.

DOI: 10.7717/peerj.7564/supp-1